CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. High bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. High threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increased Drug Development Activities
3.4.1.2. Patient Compliance offered by pharmaceutical suspensions
3.4.1.3. Availability of generic pharmaceutical suspensions
3.4.2. Restraints
3.4.2.1. Limited drug compatibility
3.4.3. Opportunities
3.4.3.1. Growing initiatives for market expansion
CHAPTER 4: PHARMACEUTICAL SUSPENSION MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Oral
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Parenteral
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Infectious Diseases
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Cancer
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Gastrointestinal
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Neurological
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Others
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
CHAPTER 6: PHARMACEUTICAL SUSPENSION MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals and Clinics
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Home Care Settings
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Others
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospital Pharmacies
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Drug Store and Retail Pharmacies
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Online Providers
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: PHARMACEUTICAL SUSPENSION MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by Type
8.2.3. Market size and forecast, by Indication
8.2.4. Market size and forecast, by End User
8.2.5. Market size and forecast, by Distribution Channel
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by Type
8.2.6.1.2. Market size and forecast, by Indication
8.2.6.1.3. Market size and forecast, by End User
8.2.6.1.4. Market size and forecast, by Distribution Channel
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by Type
8.2.6.2.2. Market size and forecast, by Indication
8.2.6.2.3. Market size and forecast, by End User
8.2.6.2.4. Market size and forecast, by Distribution Channel
8.2.6.3. Mexico
8.2.6.3.1. Market size and forecast, by Type
8.2.6.3.2. Market size and forecast, by Indication
8.2.6.3.3. Market size and forecast, by End User
8.2.6.3.4. Market size and forecast, by Distribution Channel
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by Type
8.3.3. Market size and forecast, by Indication
8.3.4. Market size and forecast, by End User
8.3.5. Market size and forecast, by Distribution Channel
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by Type
8.3.6.1.2. Market size and forecast, by Indication
8.3.6.1.3. Market size and forecast, by End User
8.3.6.1.4. Market size and forecast, by Distribution Channel
8.3.6.2. France
8.3.6.2.1. Market size and forecast, by Type
8.3.6.2.2. Market size and forecast, by Indication
8.3.6.2.3. Market size and forecast, by End User
8.3.6.2.4. Market size and forecast, by Distribution Channel
8.3.6.3. UK
8.3.6.3.1. Market size and forecast, by Type
8.3.6.3.2. Market size and forecast, by Indication
8.3.6.3.3. Market size and forecast, by End User
8.3.6.3.4. Market size and forecast, by Distribution Channel
8.3.6.4. Italy
8.3.6.4.1. Market size and forecast, by Type
8.3.6.4.2. Market size and forecast, by Indication
8.3.6.4.3. Market size and forecast, by End User
8.3.6.4.4. Market size and forecast, by Distribution Channel
8.3.6.5. Spain
8.3.6.5.1. Market size and forecast, by Type
8.3.6.5.2. Market size and forecast, by Indication
8.3.6.5.3. Market size and forecast, by End User
8.3.6.5.4. Market size and forecast, by Distribution Channel
8.3.6.6. Rest of Europe
8.3.6.6.1. Market size and forecast, by Type
8.3.6.6.2. Market size and forecast, by Indication
8.3.6.6.3. Market size and forecast, by End User
8.3.6.6.4. Market size and forecast, by Distribution Channel
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by Type
8.4.3. Market size and forecast, by Indication
8.4.4. Market size and forecast, by End User
8.4.5. Market size and forecast, by Distribution Channel
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Market size and forecast, by Type
8.4.6.1.2. Market size and forecast, by Indication
8.4.6.1.3. Market size and forecast, by End User
8.4.6.1.4. Market size and forecast, by Distribution Channel
8.4.6.2. China
8.4.6.2.1. Market size and forecast, by Type
8.4.6.2.2. Market size and forecast, by Indication
8.4.6.2.3. Market size and forecast, by End User
8.4.6.2.4. Market size and forecast, by Distribution Channel
8.4.6.3. India
8.4.6.3.1. Market size and forecast, by Type
8.4.6.3.2. Market size and forecast, by Indication
8.4.6.3.3. Market size and forecast, by End User
8.4.6.3.4. Market size and forecast, by Distribution Channel
8.4.6.4. Australia
8.4.6.4.1. Market size and forecast, by Type
8.4.6.4.2. Market size and forecast, by Indication
8.4.6.4.3. Market size and forecast, by End User
8.4.6.4.4. Market size and forecast, by Distribution Channel
8.4.6.5. South Korea
8.4.6.5.1. Market size and forecast, by Type
8.4.6.5.2. Market size and forecast, by Indication
8.4.6.5.3. Market size and forecast, by End User
8.4.6.5.4. Market size and forecast, by Distribution Channel
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Market size and forecast, by Type
8.4.6.6.2. Market size and forecast, by Indication
8.4.6.6.3. Market size and forecast, by End User
8.4.6.6.4. Market size and forecast, by Distribution Channel
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by Type
8.5.3. Market size and forecast, by Indication
8.5.4. Market size and forecast, by End User
8.5.5. Market size and forecast, by Distribution Channel
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Market size and forecast, by Type
8.5.6.1.2. Market size and forecast, by Indication
8.5.6.1.3. Market size and forecast, by End User
8.5.6.1.4. Market size and forecast, by Distribution Channel
8.5.6.2. Saudi Arabia
8.5.6.2.1. Market size and forecast, by Type
8.5.6.2.2. Market size and forecast, by Indication
8.5.6.2.3. Market size and forecast, by End User
8.5.6.2.4. Market size and forecast, by Distribution Channel
8.5.6.3. South Africa
8.5.6.3.1. Market size and forecast, by Type
8.5.6.3.2. Market size and forecast, by Indication
8.5.6.3.3. Market size and forecast, by End User
8.5.6.3.4. Market size and forecast, by Distribution Channel
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Market size and forecast, by Type
8.5.6.4.2. Market size and forecast, by Indication
8.5.6.4.3. Market size and forecast, by End User
8.5.6.4.4. Market size and forecast, by Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product mapping of top 10 player
9.4. Competitive dashboard
9.5. Competitive heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Pfizer Inc.
10.1.1. Company overview
10.1.2. Key executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.2. Merck & Co., Inc.
10.2.1. Company overview
10.2.2. Key executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. AstraZeneca plc
10.3.1. Company overview
10.3.2. Key executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.4. Eli Lilly and Company.
10.4.1. Company overview
10.4.2. Key executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. Bayer AG
10.5.1. Company overview
10.5.2. Key executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.6. Sanofi
10.6.1. Company overview
10.6.2. Key executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. Lupin
10.7.1. Company overview
10.7.2. Key executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.7.7. Key strategic moves and developments
10.8. Glenmark Pharmaceuticals Limited
10.8.1. Company overview
10.8.2. Key executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.8.7. Key strategic moves and developments
10.9. Novartis AG
10.9.1. Company overview
10.9.2. Key executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.10. Teva Pharmaceutical Industries Limited
10.10.1. Company overview
10.10.2. Key executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Business performance
10.10.7. Key strategic moves and developments
| ※参考情報 薬物懸濁液とは、薬物が液体中に分散している状態のことを指します。固体の薬物が液相に均一に分散しているため、視覚的には濁った液体として見えます。この懸濁液は、薬物が腸管から効率的に吸収されるための形態として広く用いられています。特に、固形の薬剤が苦味や不溶性を持つ場合、懸濁液が効果的です。 薬物懸濁液にはいくつかの種類があります。一般的には、親水性懸濁液と疎水性懸濁液に分けられます。親水性懸濁液は水を基盤としたもので、主に水溶性の薬物が使用されます。一方、疎水性懸濁液はオイルや界面活性剤を使用し、脂溶性の薬物を含むことが多いです。また、医薬品の特性に応じて、異なる添加剤が使用されることがあります。これには、粘度調整剤、防腐剤、pH調整剤が含まれ、懸濁液の安定性や生物利用能を向上させるために重要です。 薬物懸濁液は、さまざまな用途で用いられています。特に、小児や高齢者など、固形薬剤の服用が困難な患者に適しています。また、局所的な治療などにおいても、懸濁液形式は有用であり、皮膚科用薬や眼科用薬としても利用されています。加えて、注射剤としても開発されることがあり、この形態は特に薬物が速やかに体内に必要な効果を発揮するために設計されています。 関連技術としては、懸濁液の製造プロセスや安定性評価が 중요です。製造には、均一に分散させるためのミキサーやホモジナイザーが使用されています。これにより、粒子が適切なサイズになるように調整することが可能です。さらに、懸濁液の安定性を確保するためには、適切な保存条件や、物質の形状、成分の選定が求められます。最近では、ナノテクノロジーを用いた薬物のナノ粒子懸濁液も研究されており、これは薬物の生物利用能を向上させるための新しい手法として注目されています。 また、懸濁液の安定性向上のために、界面活性剤の使用が一般的です。これによって、粒子間の相互作用を抑制し、沈降や凝集を防ぐことができます。しかし、界面活性剤の選定には慎重さが求められ、特に生体適合性の観点から考慮しなければなりません。こうした技術革新により、懸濁液の効能や安全性が向上し、新しい治療法の開発にもつながっています。 懸濁液を用いた薬物製剤は、患者の服薬遵守を促進する手助けともなります。特に、味や香りを工夫した製剤は、より多くの患者に受け入れられやすくなります。近年では、様々なカスタマイズが可能な製剤として、パーソナライズドメディスンの一環としても期待が寄せられています。 さらに、薬物懸濁液に関連する研究は進行中であり、新しい製造方法や評価技術の開発が進められています。これにより、効率的で効果的な薬物治療が実現されることが期待されます。薬物懸濁液は、今後の医療の発展において重要な役割を果たすでしょう。患者にとっても、より安全で効果的な治療が受けられることが、医療界全体にとっての目標となっています。 |
